



# Annual Report

June 19, 2019 11:00 AM EDT

Released : June 19, 2019 07:00

RNS Number : 7254C

MaxCyte, Inc.

19 June 2019

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **2018 Annual Report**

**Gaithersburg, Maryland - 19 June 2019:** MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that copies of the 2018 Annual Report and Accounts have been sent to Stockholders and are available on the "Investors" section of the Company's website at [www.maxcyte.com](http://www.maxcyte.com).

MaxCyte also announces that its Annual General Meeting of Stockholders is planned to be held on 31 October 2019. Formal notice and resolutions, along with the Annual Meeting Proxy Card, will be circulated in September 2019 to Stockholders of record at that time.

#### **About MaxCyte**

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering

potentially more than 30 products with aggregate potential milestones of more than \$250M. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

For further information, please contact:

**MaxCyte Inc.**

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Joint Corporate Broker***

**Panmure Gordon**

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

**Corporate Broking**

James Stearns

***Joint Corporate Broker***

**Numis Securities Limited**

+44 (0)20 7260 1000

James Black

Duncan Monteith

***Financial PR Adviser***

**Consilium Strategic Communications**

+44 (0)203 709 5700

Mary-Jane Elliott

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Chris Welsh

Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

ACSGUGDLXUBBGCC